A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: PF-03084014
- drug: PF-03084014
- drug: PF-03084014
- drug: Docetaxel
- drug: Docetaxel
Eligibility
Inclusion Criteria:
- Diagnosis of breast cancer with evidence of a) metastatic or b) locally
recurrent/advanced disease.
Exclusion Criteria:
- Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.